A Phase 1 Study of CRD3874-SI in People With Advanced Sarcoma or Merkel Cell Cancer

Full Title

A Phase I Trial of CRD3874-SI, a STING Agonist, in Patients With Advanced/Metastatic Malignant Solid Tumors

Purpose

Researchers want to find the best dose of CRD3874-SI to use in people with sarcoma or Merkel cell carcinoma (MCC). The people in this study have sarcoma or MCC that has spread. CRD3874-SI attaches to a type of protein called a STING. This protein encourages immune cells to kill cancer cells, which may slow or stop cancer growth. CRD3874-SI is given intravenously (by vein).

Contact

For more information or to see if you can join this study, please call Dr. Ciara Kelly’s office at 646-888-4312.

Protocol
23-169
Phase
Phase I (phase 1)
Disease Status
Relapsed or Refractory
Investigator
Ciara Kelly
Co-Investigators
Christopher A. Barker
Sandra P. D'Angelo
Robert Maki
Diseases
Merkel Cell Carcinoma
Sarcomas
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT06021626
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description